Literature DB >> 8394159

Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis.

M E Westarp1, P Bartmann, J Rössler, E Geiger, K P Westphal, H Schreiber, D Fuchs, M P Westarp, H H Kornhuber.   

Abstract

Clinical and experimental findings in idiopathic amyothrophic lateral sclerosis (ALS) would be compatible with a retroviral involvement. In 35 adult patients with non-familial ALS we observed elevated circulating immune complexes, a decrease in IgG3 isotype and enzyme-linked sorbent assay (ELISA) serum antibodies against human spuma retrovirus (HSRV), confirmed by specific human foamy virus immunoblots. All 35 were negative for IgM or relevant IgG anti-ganglioside antibodies. We treated 12 HIV-negative, immune-complex-positive ALS patients with 500 mg d-1 zidovudine p.o. over 2-10 months and found reductions of serum creatine kinase and circulating immune complexes from two days to two weeks after the beginning of medication.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394159     DOI: 10.1097/00001756-199306000-00056

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  5 in total

Review 1.  Immunological findings in amyotrophic lateral sclerosis.

Authors:  J P Antel; N R Cashman
Journal:  Springer Semin Immunopathol       Date:  1995

Review 2.  Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis.

Authors:  Wenxue Li; Darshan Pandya; Nicholas Pasternack; Marta Garcia-Montojo; Lisa Henderson; Christine A Kozak; Avindra Nath
Journal:  Neurotherapeutics       Date:  2022-04-12       Impact factor: 6.088

Review 3.  Retroviruses and amyotrophic lateral sclerosis.

Authors:  Tariq Alfahad; Avindra Nath
Journal:  Antiviral Res       Date:  2013-05-23       Impact factor: 5.970

4.  Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy.

Authors:  M Garcia-Montojo; S Fathi; G Norato; B R Smith; D B Rowe; M C Kiernan; S Vucic; S Mathers; R P A van Eijk; U Santamaria; M-L Rogers; A Malaspina; V Lombardi; P R Mehta; H-J Westeneng; L H van den Berg; A Al-Chalabi; J Gold; A Nath
Journal:  J Neurol Sci       Date:  2021-02-23       Impact factor: 3.181

Review 5.  A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis.

Authors:  Georgios Pampalakis; Georgios Angelis; Eleni Zingkou; Kostas Vekrellis; Georgia Sotiropoulou
Journal:  Clin Transl Med       Date:  2022-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.